Daniel Guinart
Overview
Explore the profile of Daniel Guinart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verdoux H, Bittner R, Hasan A, Qubad M, Wagner E, Lepetit A, et al.
Eur Psychiatry
. 2025 Jan;
68(1):e17.
PMID: 39788917
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of...
2.
Solmi M, Thompson T, Cortese S, Estrade A, Agorastos A, Radua J, et al.
J Am Acad Child Adolesc Psychiatry
. 2024 Nov;
PMID: 39581373
Objective: To identify the COVID-19 pandemic impact on well-being/mental health, coping strategies, and risk factors in adolescents worldwide. Method: This study was based on an anonymous online multi-national/multi-language survey in...
3.
Catalan A, Salazar de Pablo G, Aymerich C, Guinart D, Goena J, Madaria L, et al.
Schizophr Bull
. 2024 Nov;
PMID: 39580760
Background And Hypothesis: Duration of untreated psychosis (DUP) has been linked to worse mental health outcomes in psychotic disorders. We meta-analytically studied the relationship between "long" vs. "short" DUP and...
4.
Solmi M, Thompson T, Cortese S, Estrade A, Agorastos A, Radua J, et al.
Eur Neuropsychopharmacol
. 2024 Sep;
90:1-15.
PMID: 39341043
There is no multi-country/multi-language study testing a-priori multivariable associations between non-modifiable/modifiable factors and validated wellbeing/multidimensional mental health outcomes before/during the COVID-19 pandemic. Moreover, studies during COVID-19 pandemic generally do not...
5.
Solmi M, Thompson T, Estrade A, Agorastos A, Radua J, Cortese S, et al.
Psychiatry Res
. 2024 Sep;
342:115972.
PMID: 39305825
International studies measuring wellbeing/multidimensional mental health before/ during the COVID-19 pandemic, including representative samples for >2 years, identifying risk groups and coping strategies are lacking. COH-FIT is an online, international,...
6.
Mortier P, Conde S, Alayo I, Amigo F, Ballester L, Cirici Amell R, et al.
JAMA Netw Open
. 2024 Jun;
7(6):e2417131.
PMID: 38922620
Importance: There is a need for representative research on serious adverse outcomes following discharge from psychiatric hospitalization. Objective: To compare rates of premature death, suicide, and nonlethal intentional self-harm after...
7.
Guinart D, Fagiolini A, Fusar-Poli P, Giordano G, Leucht S, Moreno C, et al.
Neuropsychiatr Dis Treat
. 2024 May;
20:1139-1152.
PMID: 38812809
Introduction: Schizophrenia is a severe mental illness that usually begins in late adolescence or early adulthood. Current pharmacological treatments, while acceptably effective for many patients, are rarely clinically tailored or...
8.
Aust B, Leduc C, Cresswell-Smith J, OBrien C, Rugulies R, Leduc M, et al.
Int Arch Occup Environ Health
. 2024 May;
97(5):485-522.
PMID: 38695906
Objective: To determine if and which types of organisational interventions conducted in small and medium size enterprises (SMEs) in healthcare are effective on mental health and wellbeing. Methods: Following PRISMA...
9.
Salazar de Pablo G, Guinart D, Armendariz A, Aymerich C, Catalan A, Alameda L, et al.
Schizophr Bull
. 2024 Mar;
50(4):771-783.
PMID: 38491933
Background: The role of duration of untreated psychosis (DUP) as an early detection and intervention target to improve outcomes for individuals with first-episode psychosis is unknown. Study Design: PRISMA/MOOSE-compliant systematic...
10.
Talavera A, Palmada-Flores M, Burriel-Carranza B, Valbuena-Urena E, Mochales-Riano G, Adams D, et al.
iScience
. 2024 Jan;
27(1):108665.
PMID: 38226169
The Montseny brook newt (), considered the most endangered amphibian in Europe, is a relict salamandrid species endemic to a small massif located in northeastern Spain. Although conservation efforts should...